Apogee Therapeutics, Inc.
APGE
Rank in Stocks
#2358
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Share Price
$135.07
Last synced: 2026-09-04
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
144.91%
Country
US
Trade Apogee Therapeutics, Inc. (APGE)
Category
Healthcare
Dividend yield history for Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (stock symbol: APGE) dividend yield (TTM) as of 2023-12-31: 0.00%
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Apogee Therapeutics, Inc. (APGE) from 2022 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
